Maas Matthew B, Furie Karen L
175 Cambridge Street, Suite 300, Boston, MA 02114, USA, Tel.: +1 617 643 2713; ;
Biomark Med. 2009 Aug 1;3(4):363-383. doi: 10.2217/bmm.09.30.
Serum biomarkers related to the cascade of inflammatory, hemostatic, glial and neuronal perturbations have been identifed to diagnose and characterize intracerebral hemorrhage and cerebral ischemia. Interpretation of most markers is confounded by their latent rise, blood-brain barrier effects, the heterogeneity of etiologies and the wide range of normal values, limiting their application for early diagnosis, lesion size estimation and long-term outcome prediction. Certain hemostatic and inflammatory constituents have been found to predict response to thrombolysis and worsening due to infarct progression and secondary hemorrhage, offering a potential role for improved treatment selection and individualization of therapy. Biomarkers will become increasingly relevant for developing targets for neuroprotective therapies, monitoring response to treatment and as surrogate end points for treatment trials.
与炎症、止血、神经胶质和神经元紊乱级联相关的血清生物标志物已被确定用于诊断和表征脑出血和脑缺血。大多数标志物的解释因其潜在升高、血脑屏障效应、病因异质性和正常范围广泛而受到混淆,限制了它们在早期诊断、病变大小估计和长期预后预测中的应用。已发现某些止血和炎症成分可预测溶栓反应以及梗死进展和继发性出血导致的病情恶化,为改善治疗选择和治疗个体化提供了潜在作用。生物标志物对于开发神经保护治疗靶点、监测治疗反应以及作为治疗试验的替代终点将变得越来越重要。